Title:
USE OF AN MAO-A OR MAO-B INHIBITOR FOR THE TREATMENT OF VASCULAR DISORDERS
Document Type and Number:
WIPO Patent Application WO1999037293
Kind Code:
A3
Abstract:
Effects of MAO-A or MAO-B inhibitors such as L-deprenyl on both cerebral and peripheral vasculature, on non-vascular smooth muscle, on the nervous system, and on platelets, RBC, WBC, mast cells, macrophages, and glial cells are disclosed. The effects are the result of a mode of action for MAO-A or MAO-B inhibitors such as L-deprenyl which is totally unrelated to selective inhibition of MAO-A and/or MAO-B. Therapeutic methods of using MAO-A or MAO-B inhibitors such as L-deprenyl to treat a variety of disorders are disclosed.
Inventors:
THOMAS THOMAS N (US)
Application Number:
PCT/US1999/001670
Publication Date:
April 20, 2000
Filing Date:
January 26, 1999
Export Citation:
Assignee:
THOMAS THOMAS N (US)
International Classes:
A61K31/00; A61K31/135; A61K31/137; A61K31/138; A61K31/165; A61K31/166; A61K31/425; A61K31/426; (IPC1-7): A61K31/135; A61K31/165; A61K31/425
Domestic Patent References:
| WO1996012472A1 | 1996-05-02 | |||
| WO1992017169A1 | 1992-10-15 | |||
| WO1997028791A1 | 1997-08-14 | |||
| WO1995011016A1 | 1995-04-27 | |||
| WO1997017346A1 | 1997-05-15 |
Foreign References:
| DE1593478A1 | 1970-10-22 | |||
| FR1494630A | 1967-09-08 | |||
| GB1199330A | 1970-07-22 | |||
| US3946060A | 1976-03-23 | |||
| EP0531155A1 | 1993-03-10 | |||
| US3217011A | 1965-11-09 | |||
| US3580921A | 1971-05-25 | |||
| GB1438099A | 1976-06-03 | |||
| GB1576660A | 1980-10-15 |
Other References:
FUKASAWA I ET AL: "THE CENTRAL MECHANISM OF THE HYPOTENSIVE EFFECTS OF CLORGYLINE AND DEPRENYL IN SPONTANEOUSLY HYPERTENSIVE RATS", BIOGENIC AMINES, vol. 6, no. 6, November 1989 (1989-11-01), pages 549 - 558, XP002109583
CRISCIONE L ET AL: "CENTRAL ANTI HYPERTENSIVE EFFECTS OF MONO AMINE OXIDASE INHIBITORS ASSOCIATED WITH MONO AMINE OXIDASE A NOT MONO AMINE OXIDASE B INHIBITION", FALL MEETING OF THE DEUTSCHE PHARMAKOLOGISCHE GESELLSCHAFT (GERMAN PHARMACOLOGICAL SOCIETY), VIENNA, SEPT. 20-23, 1982. NAUNYN-SCHMIEDEBERG'S ARCH PHARMACOL, VOL 321(SUPPLEMENT),P. R18, ABSTR.NO.72, XP002109584
FUENTES J A ET AL: "INHIBITION BY PARGYLINE OF CARDIO VASCULAR AMINE OXIDASE ACTIVITY", BIOCHEM PHARMACOL., VOL.26(22)1977,PP.2107-12, XP002109585
SUTNICK AI ET AL: "Antihypertensive effect of pargyline and methyclothiazide in combination.", VASC DIS, JUN 1966, 3 (3) P145-55, UNITED STATES, XP002109586
SUTNICK, A.I. ET AL: "Pargyline hydrochloride in hypertension", CLINICAL MEDICINE, vol. 72, no. 12, 1965, pages 1933 - 1938, XP002109587
FUENTES JA ET AL: "Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats.", EUR J PHARMACOL, JUL 15 1979, 57 (1) P21-7, NETHERLANDS, XP002109588
DOSTERT P.: "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?", JOURNAL OF NEURAL TRANSMISSION, SUPPLEMENT,, vol. -, no. 41, August 1992 (1992-08-01), Austria, pages 269 - 279, XP002109589
SWEENEY MI ET AL: "Cellular mechanisms involved in brain ischemia.", CAN J PHYSIOL PHARMACOL, NOV 1995, 73 (11) P1525-35, CANADA, XP002109590
KNOLLEMA, S. ET AL: "L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia", STROKE, vol. 26, 1995, pages 1883 - 1887, XP002109591
THOMAS, T. ET AL: "Cerebrovascular endolthelial dysfunction mediated by beta-amyloid", NEUROREPORT, vol. 8, no. 6, 1997, pages 1387 - 1391, XP002109592
THOMAS, T. ET AL: "Beta-amyloid-mediated vasoactivity and vascular endothelial damage", NATURE, vol. 380, 14 March 1996 (1996-03-14), pages 168 - 171, XP002109593
THOMAS, . ET AL: "L-deprenyl: nitric oxide production and dilation of cerebral blood vessels", NEUROREPORT, vol. 9, 3 August 1998 (1998-08-03), pages 2595 - 2600, XP000869850
HETTS, S.W.: "To die or not to die: An overview of apoptosis and its role in disease", JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 279, no. 4, 28 January 1998 (1998-01-28), pages 300 - 307, XP000869880
CHIUEH, C.C. ET AL: "Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity", JOURNAL OF NEURAL TRANSMISSION, vol. 41, no. suppl., 1994, pages 189 - 196, XP000869881
TATTON, W.G. ET AL: "Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration", NEUROLOGY, vol. 47, no. 6 suppl. 3, December 1996 (1996-12-01), pages S171 - S183, XP000673186
ZHANG, X. ET AL: "Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl", BRAIN RESEARCH BULLETIN, vol. 38, no. 4, 1995, pages 307 - 311, XP000086989
LI, XIN-MIN ET AL: "Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-Deprenyl and other monoamine oxidase B inhibitors", JOURNAL OF NEUROCHEMISTRY, vol. 61, no. 4, 1993, pages 1573 - 1576, XP000869892
LI, XIN-MIN ET AL: "Some new mechanisms underlying the actions of (-)-deprenyl: possible relevance to neurodegeneration", PROGRESS IN BRAIN RESEARCH, vol. 106, 1995, pages 99-112, XP000869856
COSI, C. ET AL: "Poly(ADP-ribose) Polymerase (PARP) revisted", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 825, 1997, pages 366 - 379, XP000869896
MUNIRATHINAM, S. ET AL: "(-) Deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures", NEURODEGENERATION, vol. 5, no. 2, June 1996 (1996-06-01), pages 161 - 167, XP000869894
MYTILINEOU, C. ET AL: "L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro", JOURNAL OF NEUROCHEMISTRY, vol. 68, no. 1, 1997, pages 33 - 39, XP000869893
CAPRIOLOI, J.: "Neuroprotection of the optic nerve in glaucoma", ACTA OPHTHALMOLOGICA SCANDINAVICA, vol. 75, no. 4, 1997, pages 364 - 367, XP002075485
JENNER, P.: "Oxidative stress in the pathogenesis of Parkinson's disease", NEUROLOGY, vol. 47, no. suppl. 3, 1996, pages s161 - s170, XP000869851
KUSHLEIKA, J. ET AL: "Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease", ANNALS OF NEUROLOGY, vol. 39, no. 3, 1996, pages 378 - 381, XP000870462
CARILLO, M.-C. ET AL: "(-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats", LIFE SCIENCES, vol. 48, no. 6, 1991, pages 517 - 521, XP000870455
CRISCIONE L ET AL: "CENTRAL ANTI HYPERTENSIVE EFFECTS OF MONO AMINE OXIDASE INHIBITORS ASSOCIATED WITH MONO AMINE OXIDASE A NOT MONO AMINE OXIDASE B INHIBITION", FALL MEETING OF THE DEUTSCHE PHARMAKOLOGISCHE GESELLSCHAFT (GERMAN PHARMACOLOGICAL SOCIETY), VIENNA, SEPT. 20-23, 1982. NAUNYN-SCHMIEDEBERG'S ARCH PHARMACOL, VOL 321(SUPPLEMENT),P. R18, ABSTR.NO.72, XP002109584
FUENTES J A ET AL: "INHIBITION BY PARGYLINE OF CARDIO VASCULAR AMINE OXIDASE ACTIVITY", BIOCHEM PHARMACOL., VOL.26(22)1977,PP.2107-12, XP002109585
SUTNICK AI ET AL: "Antihypertensive effect of pargyline and methyclothiazide in combination.", VASC DIS, JUN 1966, 3 (3) P145-55, UNITED STATES, XP002109586
SUTNICK, A.I. ET AL: "Pargyline hydrochloride in hypertension", CLINICAL MEDICINE, vol. 72, no. 12, 1965, pages 1933 - 1938, XP002109587
FUENTES JA ET AL: "Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats.", EUR J PHARMACOL, JUL 15 1979, 57 (1) P21-7, NETHERLANDS, XP002109588
DOSTERT P.: "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?", JOURNAL OF NEURAL TRANSMISSION, SUPPLEMENT,, vol. -, no. 41, August 1992 (1992-08-01), Austria, pages 269 - 279, XP002109589
SWEENEY MI ET AL: "Cellular mechanisms involved in brain ischemia.", CAN J PHYSIOL PHARMACOL, NOV 1995, 73 (11) P1525-35, CANADA, XP002109590
KNOLLEMA, S. ET AL: "L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia", STROKE, vol. 26, 1995, pages 1883 - 1887, XP002109591
THOMAS, T. ET AL: "Cerebrovascular endolthelial dysfunction mediated by beta-amyloid", NEUROREPORT, vol. 8, no. 6, 1997, pages 1387 - 1391, XP002109592
THOMAS, T. ET AL: "Beta-amyloid-mediated vasoactivity and vascular endothelial damage", NATURE, vol. 380, 14 March 1996 (1996-03-14), pages 168 - 171, XP002109593
THOMAS, . ET AL: "L-deprenyl: nitric oxide production and dilation of cerebral blood vessels", NEUROREPORT, vol. 9, 3 August 1998 (1998-08-03), pages 2595 - 2600, XP000869850
HETTS, S.W.: "To die or not to die: An overview of apoptosis and its role in disease", JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 279, no. 4, 28 January 1998 (1998-01-28), pages 300 - 307, XP000869880
CHIUEH, C.C. ET AL: "Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity", JOURNAL OF NEURAL TRANSMISSION, vol. 41, no. suppl., 1994, pages 189 - 196, XP000869881
TATTON, W.G. ET AL: "Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration", NEUROLOGY, vol. 47, no. 6 suppl. 3, December 1996 (1996-12-01), pages S171 - S183, XP000673186
ZHANG, X. ET AL: "Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl", BRAIN RESEARCH BULLETIN, vol. 38, no. 4, 1995, pages 307 - 311, XP000086989
LI, XIN-MIN ET AL: "Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-Deprenyl and other monoamine oxidase B inhibitors", JOURNAL OF NEUROCHEMISTRY, vol. 61, no. 4, 1993, pages 1573 - 1576, XP000869892
LI, XIN-MIN ET AL: "Some new mechanisms underlying the actions of (-)-deprenyl: possible relevance to neurodegeneration", PROGRESS IN BRAIN RESEARCH, vol. 106, 1995, pages 99-112, XP000869856
COSI, C. ET AL: "Poly(ADP-ribose) Polymerase (PARP) revisted", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 825, 1997, pages 366 - 379, XP000869896
MUNIRATHINAM, S. ET AL: "(-) Deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures", NEURODEGENERATION, vol. 5, no. 2, June 1996 (1996-06-01), pages 161 - 167, XP000869894
MYTILINEOU, C. ET AL: "L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro", JOURNAL OF NEUROCHEMISTRY, vol. 68, no. 1, 1997, pages 33 - 39, XP000869893
CAPRIOLOI, J.: "Neuroprotection of the optic nerve in glaucoma", ACTA OPHTHALMOLOGICA SCANDINAVICA, vol. 75, no. 4, 1997, pages 364 - 367, XP002075485
JENNER, P.: "Oxidative stress in the pathogenesis of Parkinson's disease", NEUROLOGY, vol. 47, no. suppl. 3, 1996, pages s161 - s170, XP000869851
KUSHLEIKA, J. ET AL: "Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease", ANNALS OF NEUROLOGY, vol. 39, no. 3, 1996, pages 378 - 381, XP000870462
CARILLO, M.-C. ET AL: "(-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats", LIFE SCIENCES, vol. 48, no. 6, 1991, pages 517 - 521, XP000870455
Download PDF: